Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fludrocortisone acetate
Drug ID BADD_D00918
Description Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.[A5423]
Indications and Usage For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
Marketing Status Prescription; Discontinued
ATC Code H02AA02
DrugBank ID DB00687
KEGG ID D00986
MeSH ID C034635
PubChem ID 225609
TTD Drug ID Not Available
NDC Product Code 69238-7033; 68084-288; 58159-074; 0115-7033; 55154-6645; 42291-764; 49452-3155; 51927-2408; 50268-330; 63629-8806; 71335-0976; 63629-7780; 14096-127; 42291-529; 46439-8721; 0615-6562; 38779-0129; 65089-0015; 62991-2773; 0555-0997
Synonyms fludrocortisone acetate | fluorocortisol acetate | fludrocortisone 21-acetate | 9 alpha-fluorocortisol acetate | Florinef | Cortineff
Chemical Information
Molecular Formula C23H31FO6
CAS Registry Number 514-36-3
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(C3(C2CCC4=CC(=O)CCC43C)F)O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypernatraemia14.05.04.001--
Hypertension24.08.02.001--
Hypopituitarism05.03.02.001--
Impaired healing08.03.02.001--Not Available
Increased insulin requirement05.06.01.006; 14.06.01.006--Not Available
Infection11.01.08.002--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Lipoatrophy14.08.04.006; 23.07.01.001--
Measles23.09.03.009; 11.05.19.001--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Muscular weakness17.05.03.005; 15.05.06.001--
Myopathy15.05.05.001--Not Available
Nitrogen balance negative13.13.01.010--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oesophagitis07.08.05.001--
Optic neuritis17.04.05.001; 10.04.10.002; 06.04.08.002--Not Available
Osteonecrosis24.04.05.004; 15.02.04.007--
Osteoporosis15.02.03.002; 14.04.04.002--
Pancreatitis07.18.01.001--
Papilloedema24.03.07.001; 17.07.02.004; 06.09.02.002--
Pathological fracture15.08.02.008; 12.04.02.006; 16.32.03.007--Not Available
Peptic ulcer07.04.07.001--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Secondary adrenocortical insufficiency14.11.01.014; 05.01.02.003--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages